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Magnetic hyperthermia ͑MH͒ using a superparamagntice nanoparticle agent ͑SPNA͒ has recently drawn huge attraction due to its clinical promises.
1,2 Accordingly, the interests to utilize the ternary phase of SPNPs, MFe 2 O 4 ͑M = Fe, Co, Ni, and Mg͒, with a mean diameter below 10 nm for a MH agent has increased dramatically. However, despite their promising chemical, physiological, biotechnical, and physical properties suitable for SPNA applications, 3 an insufficient ⌬T ac,mag and low specific absorption rate ͑SAR͒ at the physiologically tolerable range of frequencies and magnetic fields ͑f appl Ͻ 100 kHz, H appl Ͻ 200 Oe͒ are still revealed as the technical challenges to be overcome for a real clinical MH. 4, 5 Thus, a great deal of research activity is being conducted in order to develop a functional SPNA and to improve the efficiency of currently used ferrite SPNAs. The quarterly phase of bulk Mn x Zn 1−x Fe 2 O 4 , which is one of the softest ͑or the highest permeability͒ ferrite materials, is considered to be a potential material for MH agent. The main physical reason is that it has a good electrical field absorption and a large power loss ͑500-200 W / m 3 ͒ at a low frequency ͑Ͻ100 kHz͒ which is due to its low electrical resistivity ͑0.02-20 ⍀ m͒. 6, 7 Furthermore, its magnetic properties, i.e., saturation magnetization, M s , and magnetic susceptibility 2+ cation concentration were synthesized using a modified high temperature thermal decomposition ͑HTTD͒ method, where ramping up rate and heat treatment time were changed to 8.5°C / min and 25 min, respectively, compared to a conventional HTTD method. 11 The Mn 2+ cation concentration of Mn x Zn 1−x Fe 2 O 4 NPs was systematically controlled from x = 0.2 to 0.8 during the synthesis. The crystal structure, the particle size, and the distribution of Mn x Zn 1−x Fe 2 O 4 NPs were analyzed by using a Cu-k␣ radiated x-ray diffractometer ͑XRD͒ and a high resolution transmission electron microscopy ͑HRTEM͒. The ⌬T ac,mag characteristics and the ac magnetic hysteresis of the solid state Mn x Zn 1−x Fe 2 O 4 NPs were measured by using an ac solenoid coil system, which is connected to a capacitor. The f appl and the H appl were varied from 30 kHz to 210 kHz and from 60 Oe to 140 Oe, respectively. The dc magnetic properties of the a͒ Author to whom correspondence should be addressed. 4 NPs were analyzed by using a vibrating sample magnetometer and the ac m was measured by using an ac magnetosusceptometer. The zero field cooling/field cooling ͑ZFC/FC͒ measurement was carried out to characterize the dependence of temperature on the magnetic properties of Mn x Zn 1−x Fe 2 O 4 NPs using a superconducting quantum interference device ͑SQUID͒. The cell viability was quantitatively analyzed by employing the methylthiazol tetrazolium bromide test ͑MTT͒ using neuronal stem cells ͑NSCs͒ isolated from human fetal midbrain. The Mn x Zn 1−x Fe 2 O 4 NPs were dispersed into the mixed media of 2.5% alcohol, Dulbeco's modified eagle's medium, 10% fetal bovine serum, 1% penicillin streptomycin, and 2 mM glutamine. The concentration of Mn x Zn 1−x Fe 2 O 4 NPs in the media were varied from 5 to 25 g / ml.
Prior to studying the magnetic properties and the ⌬T ac,mag characteristics, the crystal structure, the particle size and the distribution of Mn x Zn 1−x Fe 2 O 4 NPs were first investigated. As can be seen in Fig. 1 , all of the Mn x Zn 1−x Fe 2 O 4 NPs had a mean particle size of 5.7-6 nm with a 12% standard deviation and they were well segregated with a round shapes. In addition, the Mn x Zn 1−x Fe 2 O 4 NPs showed a single phase cubic spinel ferrite structure and did not exhibit any undesirable crystalline phases. The well controlled structural and chemical stabilities of Mn x Zn 1−x Fe 2 O 4 NPs demonstrate that they can be considered to be an in vivo MH agent because they are expected to minimize the biochemical reaction with chemical components in the blood stream and to allow for stable intravenous circulation. 
FIG. 3. Dependence of Mn
2+ cation concentration on the ͑a͒ ac magnetically induced heating characteristics measured at the fixed H appl =80 Oe and f appl = 210 kHz, ͑b͒ applied frequency and magnetic field, and ͑c͒ SAR, heating power ͑total and relaxation loss͒, magnetization, out of phase susceptibility and ac magnetic coercivity of superparamagnetic Mn x Zn 1−x Fe 2 O 4 nanoparticles ͓ᮀ SAR, magnetization ͑dc͒, ᭺ P total , b P relaxation loss , ᭝ ac susceptibility, and ᭡ coercivity ͑ac͔͒. SPNPs is dominantly related to the "relaxation loss" heating power, P relaxation loss , as described in Eqs. ͑1͒ and ͑2͒. 12 Furthermore, from this point of view, the highest ⌬T ac,mag value obtained from the Mn 0.5 Zn 0.5 Fe 2 O 4 SPNP can be understood to be due to its highest measured m Љ value which resulted from its softest magnetic property as well as its largest exchange energy induced by the half portion of Zn 2+ ions replaced by the Mn 2+ ions on the A-site.
where N : Néel relaxation time, B : Brownian relaxation time, 0 :relaxation factor, and K u : magnetic anisotropy.
The ac magnetic coercivity of Mn x Zn 1−x Fe 2 O 4 SPNPs measured at H appl = Ϯ 80 Oe and f appl = 210 kHz is shown in Fig. 3͑c͒ Furthermore, this indicates that controlling the ac magnetic softness of SPNPs, which is directly relevant to the Néel relaxation behavior, is the most crucial factor in determining the ⌬T ac,mag characteristics. In order to further clarify the physical mechanism of ⌬T ac,mag of Mn x Zn 1−x Fe 2 O 4 SPNPs, the contribution of P relaxation loss to the total power heat generation, P total , was numerically compared by calculating both P total and P relaxation loss from the experimentally obtained ⌬T ac,mag , m Љ ͑at f appl = 210 kHz͒, mass, and the volumetric heat capacity values of Mn x Zn 1−x Fe 2 O 4 SPNPs. As can be seen in Fig. 3͑c͒ , more than 80% or 90% of P relaxation loss contributed to the P total of Mn x Zn 1−x Fe 2 O 4 SPNPs verifying that the P relaxation loss , particularly the Néel relaxation power loss is dominant for the ⌬T ac,mag of Mn x Zn 1−x Fe 2 O 4 SPNPs. To consider the SPNPs for a real clinical MH agent without systemic side effect, the SPNPs should generate a higher ⌬T ac,mag both in a short heat up time and with a amount as low as possible. These characteristics can be evaluated by the SAR shown in Fig. 3͑c͒ . 13 The Mn 0. Figure 4 showed the cell survival rate treated for ͑a͒ one day and ͑b͒ two weeks, respectively. It was clearly confirmed that the cell survival rate of 
